Indivior Announces Completion of Redomiciliation to the United States

Rhea-AI Summary

Indivior (Nasdaq: INDV) completed redomiciliation from the United Kingdom to the United States effective Jan 26, 2026. A new Delaware parent, Indivior Pharmaceuticals, Inc. (IPI), is now the parent and Indivior PLC was renamed Indivior Ltd. Shareholders received one IPI common share for each Indivior PLC ordinary share as of the scheme record date, and Indivior common stock remains listed on Nasdaq under INDV. IPI is now a U.S. domestic issuer subject to SEC reporting and Nasdaq exchange rules. The redomiciliation was approved at an extraordinary general meeting on Dec 11, 2025.

Positive

• Completed redomiciliation to a U.S. Delaware parent (IPI) effective Jan 26, 2026
• Indivior common stock continues to trade on Nasdaq under INDV
• Share exchange executed 1-for-1: one IPI share per Indivior PLC ordinary share
• IPI is subject to U.S. SEC domestic issuer reporting and Nasdaq rules

Negative

• None.

News Market Reaction

+1.85%

1 alert

+1.85% News Effect

On the day this news was published, INDV gained 1.85%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Last UK share trading day: January 23, 2026 EGM approval date: December 11, 2025 Share exchange ratio: 1 new share for 1 old share +4 more

7 metrics

Last UK share trading day January 23, 2026 Final trading day for Indivior PLC ordinary shares on Nasdaq

EGM approval date December 11, 2025 Extraordinary general meeting approving redomiciliation

Share exchange ratio 1 new share for 1 old share One IPI common share for each Indivior PLC ordinary share

Company history More than 25 years Time Indivior has worked in addiction medicine

Current share price $32.97 Price before redomiciliation completion announcement

52-week range $7.62–$38.00 Low and high over the last 52 weeks

Market cap $4,193,319,382 Equity value prior to announcement

Market Reality Check

Price: $34.75 Vol: Volume 1,052,170 vs 20-da...

low vol

$34.75 Last Close

Volume Volume 1,052,170 vs 20-day average 1,710,327 (relative volume 0.62). low

Technical Price 32.97 is trading above the 200-day MA of 22.42.

Peers on Argus

INDV was down 1.7% ahead of this news, while peers HCM, AMRX, BHC, SUPN, and KNS...

INDV was down 1.7% ahead of this news, while peers HCM, AMRX, BHC, SUPN, and KNSA also showed negative moves (e.g., BHC -4.98%, SUPN -1.15%), indicating a broader sector drift rather than a clearly isolated move.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Guidance & update	Positive	-1.1%	Issued 2026 revenue and EBITDA guidance plus strategic business update.
Dec 22	Index inclusion	Positive	+3.5%	Announced addition to the S&P SmallCap 600 index.
Dec 17	Clinical trial data	Positive	+1.6%	Reported positive SUBLOCADE trial outcomes with rapid opioid-use reductions.
Nov 20	DOJ matter resolved	Positive	-2.5%	Paid $295M to conclude a legacy DOJ matter using cash on hand.
Nov 19	Conference participation	Positive	+1.1%	Announced participation in Piper Sandler healthcare conference and webcast.

Pattern Detected

Positive news has sometimes seen mixed reactions, with both aligned gains and divergences where shares declined on favorable updates.

Recent Company History

Over the last few months, Indivior has reported several constructive developments, including 2026 guidance with expected adjusted EBITDA of $535M–$575M, inclusion in the S&P SmallCap 600, and positive SUBLOCADE clinical data. The company also fully paid a $295M legacy DOJ obligation using cash on hand and remained visible at investor conferences. Today’s redomiciliation completion follows the previously approved plan to re-domicile to the U.S., extending the capital-markets and governance repositioning seen in these prior announcements.

Market Pulse Summary

This announcement finalizes Indivior’s move to a U.S.-incorporated parent while keeping trading on N...

Analysis

This announcement finalizes Indivior’s move to a U.S.-incorporated parent while keeping trading on Nasdaq under INDV and providing a 1:1 share exchange for existing holders. It follows earlier shareholder approval and aligns with efforts to sharpen the company’s U.S. capital-markets presence and governance structure. Recent history includes index inclusion, 2026 guidance, and resolution of a $295M DOJ matter, highlighting both growth ambitions and risk-management actions investors can track over time.

Key Terms

redomiciliation, nasdaq, u.s. securities and exchange commission, 8-k filing, +3 more

7 terms

redomiciliation regulatory

"today announced completion of its redomiciliation from the United Kingdom to the United States."

Redomiciliation is when a company legally changes its country of incorporation while keeping the same business and assets, like moving a house to a new neighborhood but keeping the same furniture. Investors care because the company then follows a different set of laws and tax rules, which can change shareholder rights, reporting standards, dividend treatment and the ease of trading the stock, potentially affecting risk and return.

nasdaq financial

"The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

u.s. securities and exchange commission regulatory

"IPI is subject to the reporting requirements of the U.S. Securities and Exchange Commission"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

8-k filing regulatory

"Further details regarding the redomiciliation can be found in an 8-K filing made today"

A Form 8-K is a U.S. Securities and Exchange Commission report companies must file to disclose major events that happen between regular quarterly or annual filings, such as leadership changes, mergers, bankruptcy, significant contracts, or financial restatements. For investors it acts like an urgent alert or weather warning, providing timely information about developments that could quickly change a company’s outlook or stock price and helping reduce surprise risks.

forward-looking statements regulatory

"Important Cautionary Note Regarding Forward-looking Statements Certain statements contained herein are forward-looking statements."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

opioid use disorder medical

"advancing SUBLOCADE® for opioid use disorder IPI is subject to the reporting requirements"

Opioid use disorder is a medical condition where a person repeatedly seeks and uses opioid drugs despite harmful physical, social or mental effects, often involving strong cravings and withdrawal symptoms when stopping. It matters to investors because its prevalence, availability of effective treatments, regulatory responses, and legal or insurance costs can shift demand, revenue and risk across drug makers, treatment providers and insurers—like a widespread problem that reshapes an entire market.

long-acting injectable medical

"As the leader in long-acting injectable treatments for opioid use disorder (OUD)"

A long-acting injectable is a medication formulated to be given by shot that releases its active ingredient slowly over weeks or months so a patient needs fewer doses. For investors, these products can change a drug’s market value by improving patient convenience and adherence, extending patent life or pricing opportunities, and requiring different manufacturing and regulatory steps compared with daily pills — much like swapping many small payments for a single, larger subscription.

AI-generated analysis. Not financial advice.

RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation (“IPI”), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol “INDV.”

The last day of trading Indivior PLC ordinary shares on Nasdaq was January 23, 2026. Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary share held as of the scheme record date. The redomiciliation was approved by Indivior shareholders at an extraordinary general meeting (EGM) on December 11, 2025.

Indivior believes the change in domicile will expand the benefits of its U.S. stock listing, including: 

• Strengthening Indivior’s U.S. capital markets presence
• Increasing potential U.S. equity indexation
• Simplifying corporate governance and reducing complexity
• Further positioning Indivior as a U.S. based treatment innovator, enabling closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder

IPI is subject to the reporting requirements of the U.S. Securities and Exchange Commission (“SEC”) as a domestic issuer and applicable exchange rules of Nasdaq. Further details regarding the redomiciliation can be found in an 8-K filing made today with the SEC.

Important Cautionary Note Regarding Forward-looking Statements

Certain statements contained herein are forward-looking statements. Forward-looking statements include, among other things, express and implied statements pertaining to (i) our expectations regarding expected benefits of redomiciliation, (ii) potential inclusion in additional U.S. equity indices, (iii) expected simplified corporate governance and reduced complexity, (iv) expected improved positioning as a U.S.-based treatment innovator and potential closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder, and (v) statements containing the words "believe," "anticipate,” "plan,” "expect,” "intend,” "estimate,” "forecast," "strategy,” "target,” "guidance,” "outlook,” "potential,” "project,” "priority," "may,” "will,” "should,” "would,” "could,” "can,” "outlook," the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. For information about some additional risks and important factors that could affect our future results and financial condition, see the discussion of "Risk Factors" in our Annual Report on Form 10-K filed March 3, 2025, our Forms 10-Q filed May 1, 2025, July 31, 2025, and October 30, 2025, and our other filings with the SEC.

We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

For Further Information

Investors
Jason Thompson, Indivior VP Investor Relations
804-402-7123
Jason.Thompson@Indivior.com

Media
Cassie France-Kelly
804-594-0836
IndiviorMediaContacts@Indivior.com

FAQ

What did Indivior announce about its corporate domicile on Jan 26, 2026?

Indivior announced completion of redomiciliation to the U.S.; a new Delaware parent, Indivior Pharmaceuticals, Inc. (IPI), was formed.

Will Indivior shares still trade under the same ticker after redomiciliation (INDV)?

Yes. Common stock remains listed on Nasdaq and continues to trade under the symbol INDV.

How were Indivior shareholders treated in the redomiciliation?

Shareholders received one IPI common share for each Indivior PLC ordinary share held as of the scheme record date.

When did shareholders approve the redomiciliation of Indivior (INDV)?

Shareholders approved the redomiciliation at an extraordinary general meeting on Dec 11, 2025.

What regulatory reporting change applies to Indivior after redomiciliation?

IPI is now a U.S. domestic issuer and is subject to U.S. SEC reporting requirements and applicable Nasdaq exchange rules.